Benitec Biopharma Inc.

Benitec Biopharma Inc. company information, Employees & Contact Information

Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration. Benitec is using its technology, called DNA-directed RNA interference (ddRNAi) to develop a pipeline of product candidates for the treatment of several chronic and life-threatening human diseases , including oculopharyngeal muscular dystrophy (OPMD) and hepatitis B. By combining the specificity and gene silencing effect of RNAi with gene therapy, ddRNAi has the potential to produce long-lasting silencing of disease-causing genes from a single administration, which could minimize the requirement for patients to take regular doses of medicine. Benitec’s objective is to become the leader in discovering, developing, clinically validating and commercializing ddRNAi-based therapeutics for a range of human diseases with high unmet clinical need or large patient populations and, as a result, provide a better life for patients with these diseases.

Company Details

Employees
20
Founded
-
Address
3940 Trust Way, Hayward,california 94545,united States
Phone
4089602207
Email
or****@****.com.au
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Hayward, California
Looking for a particular Benitec Biopharma Inc. employee's phone or email?

Benitec Biopharma Inc. Questions

News

Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update - GlobeNewswire

Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update GlobeNewswire

BENITEC BIOPHARMA Earnings Preview: Recent $BNTC Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative

BENITEC BIOPHARMA Earnings Preview: Recent $BNTC Insider Trading, Hedge Fund Activity, and More Quiver Quantitative

Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? - Yahoo Finance

Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? Yahoo Finance

Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering - GlobeNewswire

Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering GlobeNewswire

Benitec BioPharma stock maintains Market Outperform rating at JMP - Investing.com

Benitec BioPharma stock maintains Market Outperform rating at JMP Investing.com

Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer - Seeking Alpha

Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer Seeking Alpha

Benitec Biopharma’s Oculopharyngeal Muscular Dystrophy Gene Therapy Produces Clinical Improvements in Swallowing in Phase 1b/2a Trial - CGTLive®

Benitec Biopharma’s Oculopharyngeal Muscular Dystrophy Gene Therapy Produces Clinical Improvements in Swallowing in Phase 1b/2a Trial CGTLive®

Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid clinical progress - Investing.com

Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid clinical progress Investing.com

Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update - GlobeNewswire

Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update GlobeNewswire

Benitec Biopharma Provides Operational Update and Releases its 2020 Fiscal Year-End Financial Results - PR Newswire

Benitec Biopharma Provides Operational Update and Releases its 2020 Fiscal Year-End Financial Results PR Newswire

Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering - Stock Titan

Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering Stock Titan

Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable - Nasdaq

Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable Nasdaq

Benitec Biopharma Inc. (BNTC) reports earnings - qz.com

Benitec Biopharma Inc. (BNTC) reports earnings qz.com

Companies Like Benitec Biopharma (NASDAQ:BNTC) Can Afford To Invest In Growth - Sahm

Companies Like Benitec Biopharma (NASDAQ:BNTC) Can Afford To Invest In Growth Sahm

First Patient Treated With Benitec Biopharma’s Oculopharyngeal Muscular Dystrophy Gene Therapy Shows Swallowing Improvements - CGTLive®

First Patient Treated With Benitec Biopharma’s Oculopharyngeal Muscular Dystrophy Gene Therapy Shows Swallowing Improvements CGTLive®

Janus Henderson Group PLC Expands Investment in Benitec Biopharma Inc - Yahoo Finance

Janus Henderson Group PLC Expands Investment in Benitec Biopharma Inc Yahoo Finance

Silence and Replace Gene Therapy Cleared for Oculopharyngeal Muscular Dystrophy Clinical Trial - CGTLive®

Silence and Replace Gene Therapy Cleared for Oculopharyngeal Muscular Dystrophy Clinical Trial CGTLive®

Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma Inc - Yahoo Finance

Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma Inc Yahoo Finance

Benitec Biopharma stock maintains Market Outperform rating at JMP - Investing.com

Benitec Biopharma stock maintains Market Outperform rating at JMP Investing.com

Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million - GlobeNewswire

Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million GlobeNewswire

Companies Like Benitec Biopharma (NASDAQ:BNTC) Can Afford To Invest In Growth - Sahm

Companies Like Benitec Biopharma (NASDAQ:BNTC) Can Afford To Invest In Growth Sahm

Benitec Biopharma Stock (BNTC) Surges on Potentially Groundbreaking OPMD Treatment - Nasdaq

Benitec Biopharma Stock (BNTC) Surges on Potentially Groundbreaking OPMD Treatment Nasdaq

Benitec Biopharma begins OPMD subject enrolment - Clinical Trials Arena

Benitec Biopharma begins OPMD subject enrolment Clinical Trials Arena

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phas - Stock Titan

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phas Stock Titan

Benitec Biopharma's BB-301: Potential In OPMD, But Still Too Early Stages (NASDAQ:BNTC) - Seeking Alpha

Benitec Biopharma's BB-301: Potential In OPMD, But Still Too Early Stages (NASDAQ:BNTC) Seeking Alpha

Benitec Biopharma Inc. (BNTC) Stock Analysis: Exploring A 76% Potential Upside - DirectorsTalk Interviews

Benitec Biopharma Inc. (BNTC) Stock Analysis: Exploring A 76% Potential Upside DirectorsTalk Interviews

Benitec Biopharma Inc expected to post a loss of 29 cents a share - Earnings Preview - TradingView

Benitec Biopharma Inc expected to post a loss of 29 cents a share - Earnings Preview TradingView

Benitec Biopharma’s BB-301 Study: A Potential Game-Changer for OPMD Treatment? - TipRanks

Benitec Biopharma’s BB-301 Study: A Potential Game-Changer for OPMD Treatment? TipRanks

Benitec Biopharma Inc. (BNTC) Stock Analysis: A Biotech with 101.84% Potential Upside Awaits Investor Spotlight - DirectorsTalk Interviews

Benitec Biopharma Inc. (BNTC) Stock Analysis: A Biotech with 101.84% Potential Upside Awaits Investor Spotlight DirectorsTalk Interviews

Citizens JMP Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛

Citizens JMP Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $20 富途牛牛

Benitec Biopharma releases full year 2025 financial results - MarketScreener

Benitec Biopharma releases full year 2025 financial results MarketScreener

Axovant licenses Benitec muscular dystrophy drug, continuing pivot toward gene therapies - Fierce Biotech

Axovant licenses Benitec muscular dystrophy drug, continuing pivot toward gene therapies Fierce Biotech

Duchenne Muscular Dystrophy Cell Therapy CAP-1002 Demonstrates Improvements in LVEF - CGTLive®

Duchenne Muscular Dystrophy Cell Therapy CAP-1002 Demonstrates Improvements in LVEF CGTLive®

BNTC Stock Price and Chart — NASDAQ:BNTC - TradingView

BNTC Stock Price and Chart — NASDAQ:BNTC TradingView

Benitec Biopharma (BNTC) Stock Price, News & Analysis - MarketBeat

Benitec Biopharma (BNTC) Stock Price, News & Analysis MarketBeat

Published on: 2025-07-27 21:26:15 - Jammu Links News

Published on: 2025-07-27 21:26:15 Jammu Links News

Benitec Commences Patient Dosing with TT-034 in Patients with HCV - Technology Networks

Benitec Commences Patient Dosing with TT-034 in Patients with HCV Technology Networks

Firm Focuses Operations on Gene Silencing - Genetic Engineering and Biotechnology News

Firm Focuses Operations on Gene Silencing Genetic Engineering and Biotechnology News

Benitec gets Orphan status for muscular dystrophy gene therapy - Stockhead

Benitec gets Orphan status for muscular dystrophy gene therapy Stockhead

Top Benitec Biopharma Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant